Clinical development phase 2 study

Ended Awarded Last action

Contract number
W911SR22F0014
Awardee
Awarding agency
Obligated
$93,029,233

Award facts

Opportunity
  • W911SR22R0040 Solicitation number
Contract value 86% obligated
  • $93,029,233.21 Current, with exercised options
  • $107,935,344.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
Set-aside
No set-aside
Competition
Not Available for Competition Only One Source
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Terminate for Default P00027 $0
Funding Only Action P00026 -$3,082,047
Funding Only Action P00025 $1,600,000
Other Administrative Action P00023 -$4,503,617
Funding Only Action P00022 -$6,642,388
Other Administrative Action P00024 -$2,278,058
Supplemental Agreement for work within scope P00021 $0
Supplemental Agreement for work within scope P00020 · This delivery order is for tasks associated with the development of US food and drug administration licensed monoclonal antibody countermeasure for botulinum… $0
Supplemental Agreement for work within scope P00019 · This requirement is for the development of a U.S. Food and drug administration licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure. $9,045,429
Funding Only Action P00018 · This delivery order is for tasks associated with the development of US food and drug administration licensed monoclonal antibody countermeasure for botulinum… $3,000,000
Funding Only Action P00017 · This requirement is for the development of a U.S. Food and drug administration licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure. $9,071,010
Supplemental Agreement for work within scope P00016 $0
Funding Only Action P00015 · U.S. Food and drug administration (FDA) licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure effort. $2,830,000
Funding Only Action P00014 $0
Other Administrative Action P00013 $4,752,481
Other Administrative Action P00012 -$1,441,206
Change Order P00011 $0
Supplemental Agreement for work within scope P00010 $4,424,322
Supplemental Agreement for work within scope P00009 · Cgmp DS confirmation run(s) $9,841,556
Supplemental Agreement for work within scope P00008 · Botmab clinical development phase 2 study $12,474,772
Funding Only Action P00007 · Incrementally fund program management clin 0001 and clin 0003 cgmp DS confirmation run on botmabs project. $5,565,430
Supplemental Agreement for work within scope P00006 $3,001,790
Supplemental Agreement for work within scope P00005 $2,267,674
Other Administrative Action P00004 · Botmab clinical development phase 2 study $21,060,900
Other Administrative Action P00003 · U.S. Food and drug administration (FDA) licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure $22,041,186
Other Administrative Action P00002 -$3,081,134
Other Administrative Action P00001 -$15,640,052
Original award $18,721,186
Show all 28

About this award

Written by GovTribe AI ·

The U.S. Department of Defense's Joint PEO Chemical and Biological Defense awarded a delivery order valued at $107.9 million to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) on January 4, 2022, with completion targeted for December 30, 2025. This cost-plus-fixed-fee delivery order supports Phase 2 clinical development of an FDA-licensed monoclonal antibody countermeasure against botulinum neurotoxin exposure. The work will be performed in Frederick, Maryland, and is not associated with any small business set-aside designation. This delivery order operates under one of Resilience's existing Indefinite Delivery Contracts with the Department of the Army Acquisition Support Center—a $249 million single-award vehicle established to support FDA-approved products for chemical and biological defense programs.

Resilience Government Services specializes in biomanufacturing and complex pharmaceutical development with a focus on medical countermeasures for biological threats. The company has demonstrated substantial experience delivering clinical trials, manufacturing scale-up, regulatory support, and stability testing across multiple Department of Defense and National Institutes of Health programs. Through this delivery order and related task orders under its larger IDC vehicle, Resilience continues advancing the monoclonal antibody countermeasure through clinical testing and regulatory approval processes to achieve FDA licensure for this critical biological defense medical countermeasure.

Quick answers

Who was awarded contract W911SR22F0014?

W911SR22F0014 was awarded to Resilience Government Services, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on January 4, 2022.

How much is contract W911SR22F0014 worth?

The government has obligated $93,029,233 on W911SR22F0014. Its potential value, with all options, is $107,935,344.

Which agency awarded contract W911SR22F0014?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR22F0014, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Is contract W911SR22F0014 an order under another contract?

Yes. W911SR22F0014 is a delivery order under W911SR22D0009, an indefinite delivery contract.

Was contract W911SR22F0014 competed?

The extent of competition for W911SR22F0014 was not available for competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login